Symic to Present at Upcoming May Conferences
– Chief Financial Officer Jocelyn Jackson to present at BioEquity Europe 2016 in Copenhagen and the Bay Area Biotech Forum in San Francisco –
BioEquity Europe 2016
Bay Area Biotech Forum
Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic’s proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.